TGFB1 and cancer: In addition, several strategies targeting TGF-β signaling have been used in preclinical or clinical applications, particularly in end-stage cancer, including anti-ligand antisense oligonucleotides, antibodies targeting ligands or receptors, and targeting TGF-β-receptor kinase drugs [20–24].